Braveheart Investment Group PLC - Barnsley, England-based investor in small- and medium-sized businesses - Provides update on Phasefocus Holdings Ltd, in which Braveheart has a 44% holding. Notes Phasefocus recently appointed Nexus Scientific, a specialist in cell analysis instrument sales, to represent Livecyte products in North America. Livecyte is an imaging and analysis system which uses a novel method for high fidelity quantitative imaging and microscopy. Explains Nexus will be running a series of customer workshops, conference attendances and seminars, to raise the profile and sales of Livecyte in the US. Further, notes two new Livecyte applications have been developed and are scheduled for launch before the end of 2023.
Current stock price: 12.90 pence, up 12% in London on Wednesday
12-month change: up 5.3%
By Jeremy Cutler, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Braveheart Investments (BRH)
